Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,803 | 408 | 2,356 |
| Samples | 1,094 | 210 | 864 |
| Peptides | 895 | 150 | 776 |
Function
TIAM1 · TIAM Rac1 associated GEF 1
This gene encodes a RAC1-specific guanine nucleotide exchange factor (GEF). GEFs mediate the exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP). The binding of GTP induces a conformational change in RAC1 that allows downstream effectors to bind and transduce a signal. This gene thus regulates RAC1 signaling pathways that affect cell shape, migration, adhesion, growth, survival, and polarity, as well as influencing actin cytoskeletal formation, endocytosis, and membrane trafficking. This gene thus plays an important role in cell invasion, metastasis, and carcinogenesis. In addition to RAC1, the encoded protein activates additional Rho-like GTPases such as CDC42, RAC2, RAC3 and RHOA. This gene encodes multiple protein isoforms that experience a diverse array of intramolecular, protein-protein, and phosphorylation interactions as well as phosphoinositide binding. Both the longer and shorter isoforms have C-terminal Dbl homology (DH) and pleckstrin homology (PH) domains while only the longer isoforms of this gene have the N-terminal myristoylation site and the downstream N-terminal PH domain, ras-binding domain (RBD), and PSD-95/DlgA/ZO-1 (PDZ) domain. [provided by RefSeq, Jul 2017].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000286827 | Q13009 | 1,150 | 823 |
| ENST00000541036 | Q13009 | 705 | 498 |
| ENST00000455508 | Q13009-2 | 520 | 366 |
| ENST00000636887 | A0A1B0GW57* | 428 | 296 |
Gene Properties
Recurrent Mutations
All 823 amino-acid changes on canonical ENST00000286827 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in TIAM1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in TIAM1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 3/25 12% | 0/0 0% |
| Endometrial Carcinoma | 12/42 29% | 50/612 8% |
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 34/304 11% | 69/1390 5% |
| Gastric Carcinoma | 5/74 7% | 98/1809 5% |
| Melanoma | 13/210 6% | 102/1899 5% |
| Colorectal Carcinoma | 29/143 20% | 135/3239 4% |
| Squamous Cell Lung Carcinoma | 4/57 7% | 34/810 4% |
| Bladder Carcinoma | 6/58 10% | 33/956 3% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Cervical Carcinoma | 5/35 14% | 11/422 3% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 4/133 3% |
| Other Solid Cancers | 4/94 4% | 43/1515 3% |
| Esophageal Carcinoma | 2/23 9% | 21/769 3% |
| Neuroendocrine Tumour | 12/154 8% | 8/577 1% |
| Unknown | 1/10 10% | 0/29 0% |
| Plasma Cell Myeloma | 2/44 5% | 6/305 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Burkitts Lymphoma | 3/32 9% | 2/196 1% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Mesothelioma | 2/62 3% | 2/165 1% |
| Head and Neck Carcinoma | 2/85 2% | 25/1574 2% |
| Small Cell Lung Carcinoma | 1/9 11% | 11/752 1% |
| Meningioma | 1/3 33% | 3/252 1% |
| Other Sarcomas | 2/69 3% | 10/699 1% |
| Ovarian Carcinoma | 7/109 6% | 10/998 1% |
| Hodgkins Lymphoma | 2/16 12% | 0/122 0% |
| Glioma | 4/52 8% | 26/2127 1% |
| Ewings Sarcoma | 1/63 2% | 3/262 1% |
| Non-Cancerous | 1/104 1% | 10/830 1% |
Mutation Distribution
Where TIAM1 is mutated · all tissues, split by cell line vs tissue
How many mutations in TIAM1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,803 mutations in TIAM1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|